Mechanisms and Synergy

• BPC-157: A stable gastric pentadecapeptide shown to accelerate angiogenesis, fibroblast migration, and epithelial repair via modulation of VEGFR2, FAK-paxillin pathways, and nitric oxide signaling. It enhances tendon, muscle, and intestinal healing in preclinical models.
• TB-500 (Thymosin Beta-4): A 43-amino acid actin-sequestering peptide that promotes tissue regeneration through cell migration, angiogenesis (via VEGF upregulation), and anti-inflammatory effects. It mobilizes progenitor cells and accelerates repair of myocardium, dermis, and connective tissue.
• GHK-Cu: A copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that stimulates wound healing, collagen synthesis, and hair growth. It modulates gene expression linked to tissue remodeling and exerts antioxidant and anti-inflammatory effects through TGF-β and metalloproteinase regulation.

Synergistic Benefits:
Combined research with BPC-157, TB-500, and GHK-Cu may offer synergistic tissue regeneration and anti-inflammatory benefits by concurrently activating multiple repair pathways:

• Angiogenesis: TB-500 and BPC-157 both promote VEGF-mediated vascularization, while GHK-Cu enhances endothelial cell proliferation.
• Cellular migration and matrix remodeling: TB-500 improves actin polymerization and cellular motility; GHK-Cu and BPC-157 stimulate ECM production and fibroblast activity.
• Anti-inflammatory modulation: All three reduce oxidative stress and cytokine-driven inflammation, potentially improving healing in chronic or complex injuries.

This multifactorial synergy suggests enhanced efficacy in musculoskeletal, dermatological, and post-surgical recovery applications.

FOR RESEARCH ONLY

FDA DISCLAIMER

The information provided on this website has not been evaluated by the U.S. Food and Drug Administration (FDA). None of the statements herein, nor any of the products offered, are intended to diagnose, treat, cure, or prevent any medical condition.

All products are supplied strictly as laboratory research reagents and are not for human consumption. We do not provide products to patients and do not make any claims regarding medical use.

PharmaPure Peptide operates solely as a chemical supplier. It is not a compounding pharmacy and does not operate as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.